#Women's health
HSDD, menopause, sexual function and the peptide options indicated for them.
Incretin Therapy Before Pregnancy in PCOS
A target trial emulation linked preconception incretin therapy with fewer adverse pregnancy outcomes than metformin, but it cannot prove causation.
PT-141 for male ED: what the FDA says
PT-141 is FDA-approved for low sexual desire in premenopausal women, not male erectile dysfunction, and the off-label male use has far thinner evidence.
Semaglutide and Postmenopausal Bleeding
A new case report ties semaglutide to postmenopausal bleeding, but proving cause and effect from one patient is another matter.
GLP-1 and PCOS: Reading a New Letter
A 2026 letter raises a possible GLP-1 and PCOS association, but genetic and reporting evidence cannot establish cause or guide treatment.
Semaglutide pregnancy case series
A 2026 case series reported outcomes after first-trimester semaglutide exposure in 16 pregnancies. The result is useful but cannot establish safety.
Semaglutide plus exercise in rats
A four-week rat study found partly distinct metabolic effects from semaglutide and aerobic training, with no direct evidence for menopausal women.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
GLP-1 drugs, PCOS, and trying to conceive
GLP-1 medicines such as semaglutide are not approved to treat PCOS, and current labels require stopping the drug before a planned pregnancy.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.